DeepMed Research

MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

Comparison of Two Behavioral Treatments for Stress Reduction

Not Applicable

Completed

Conditions: Stress

Interventions: Behavioral: RR
Behavioral: MBSR

First Posted Date: 2008-02-28

Last Posted Date: 2018-08-07

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 50

Registration Number: NCT00625807

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Comparison of DSCT With IB-IVUS and Angiography in the Assessment of Coronary Artery Disease

Not Applicable

Terminated

Conditions: Coronary Artery Disease

Interventions: Device: Integrated Backscatter IVUS
Device: Dual Source Computed Tomography

First Posted Date: 2008-02-22

Last Posted Date: 2012-02-03

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 24

Registration Number: NCT00622167

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis

Phase 1

Terminated

Conditions: Chronic Pancreatitis

Interventions: Drug: RG1068 (Synthetic Human Secretin)

First Posted Date: 2008-02-22

Last Posted Date: 2009-01-29

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT00620919

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population

Phase 1

Terminated

Conditions: Acute Recurrent Pancreatitis
Chronic Pancreatitis

Interventions: Drug: RG1068 (Synthetic Human Secretin)

First Posted Date: 2008-02-22

Last Posted Date: 2009-01-29

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT00621283

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas

Phase 1

Terminated

Conditions: Intraductal Papillary Mucinous Neoplasms

Interventions: Drug: RG1068 (Synthetic Human Secretin)

First Posted Date: 2008-02-22

Last Posted Date: 2009-01-29

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 2

Registration Number: NCT00621556

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder

Phase 4

Completed

Conditions: Smoking
Bipolar Disorder
Schizoaffective Disorder
Schizophrenia

Interventions: Drug: Placebo
Drug: Varenicline

First Posted Date: 2008-02-22

Last Posted Date: 2017-12-21

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 247

Registration Number: NCT00621777

Locations: 🇺🇸
Centerstone Research Institute, Bloomington, Indiana, United States
🇺🇸
University of Minnesota Psychological Clinic, Minneapolis, Minnesota, United States
🇺🇸
West Central Behavioral Health, Claremont, New Hampshire, United States

and more 7 locations

Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia

Interventions: Dietary Supplement: Folic Acid
Other: Placebo
Dietary Supplement: B12

First Posted Date: 2008-02-11

Last Posted Date: 2014-08-19

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 140

Registration Number: NCT00611806

Locations: 🇺🇸
Massachusetts General Hospital Schizophrenia Program - Freedom Trail Clinic, Boston, Massachusetts, United States
🇺🇸
URMC Severe Mental Disorders Program, Rochester, New York, United States
🇺🇸
Touchstone innovare, Grand Rapids, Michigan, United States

Coenzyme Q10 in Huntington's Disease (HD)

Phase 3

Terminated

Conditions: Huntington's Disease

Interventions: Other: placebo
Drug: coenzyme Q10

First Posted Date: 2008-02-06

Last Posted Date: 2016-03-30

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 609

Registration Number: NCT00608881

Locations: 🇺🇸
Emory University, Wesley Woods Center, 1841 Clifton Road NE Room 314, Atlanta, Georgia, United States
🇺🇸
Idaho Elks Rehabilitation Hospital, 600 North Robbins Road, Boise, Idaho, United States
🇺🇸
University of Maryland School of Medicine, 22 South Greene Street, N4 W49-B, Baltimore, Maryland, United States

and more 46 locations

Determination of Dosing and Frequency of BCG Administration to Alter T-Lymphocyte Profiles in Type I Diabetics

Phase 1

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Biological: BCG
Biological: Saline

First Posted Date: 2008-02-05

Last Posted Date: 2013-11-05

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 25

Registration Number: NCT00607230

Locations: 🇺🇸
Diabetes Research Center at Massachusetts General Hospital, Boston, Massachusetts, United States

Validation of a New Device to Measure Neuromuscular Disease Progression

Completed

Conditions: Amyotrophic Lateral Sclerosis & Other Neuromuscular Disorders

First Posted Date: 2008-02-05

Last Posted Date: 2011-05-12

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 120

Registration Number: NCT00606918

Locations: 🇺🇸
Massachusetts General Hospital - East, Charlestown, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy